Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
2273 Research Blvd, Suite 400, Rockville, Maryland, 20850
Website
emergentbiosolutions.com
Telephone
1 301 7951800
No of Employees
2,416
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EBS (NYSE)
Revenue (2021)
$1.8B
15.3%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-24.3%
(2021 vs 2020)
Market Cap*
$1.5B
Net Profit Margin (2021)
XXX
-34.4%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| BioThrax - Anthrax Vaccine | ACAM2000 |
| ACAM2000 - Smallpox (Vaccinia) Vaccine | Anthrasil |
| Anthrasil - Inhalational Anthrax | Bat |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In May, the company entered into an agreement to acquire exclusive worldwide rights to TEMBEXA (brincidofovir) from Chimerix Inc, a biotechnology company. |
| 2022 | Others | In March, the company initiated the Phase 1 study for evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN) aginst the treatment of acute cyanide poisoning. |
| 2021 | Others | In December, the company initiated Phase 1 study on evaluating the safety, tolerability, and immunogenicity of the universal influenza vaccine candidate against influenza A viruses. |
Competitor Comparison
| Key Parameters | Emergent BioSolutions Inc | Novartis AG | Merck & Co Inc | GSK plc | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United Kingdom | United States of America |
| City | Rockville | Basel | Whitehouse Station | Brentford | Thousand Oaks |
| State/Province | Maryland | - | New Jersey | - | California |
| No. of Employees | 2,416 | 110,000 | 68,000 | 90,096 | 24,200 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zsolt Harsanyi, Ph.D. | Chairman | Executive Board | 2022 | 78 |
| Robert G. Kramer | President; Director; Chief Executive Officer | Executive Board | 2019 | 64 |
| Richard S. Lindahl | Treasurer; Executive Vice President; Chief Financial Officer | Senior Management | 2018 | 58 |
| Adam R. Havey | Chief Operating Officer; Executive Vice President | Senior Management | 2021 | 51 |
| Howard Anderson | Senior Vice President; Chief Information Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer